1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Australia >
  5. Cosette Pharmaceuticals Acquires Mayne Pharma

M&A Deal Summary

Cosette Pharmaceuticals Acquires Mayne Pharma

On February 20, 2025, Cosette Pharmaceuticals acquired life science company Mayne Pharma for 430M USD

Acquisition Highlights
  • This is Cosette Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is Cosette Pharmaceuticals’ largest (disclosed) transaction.
  • This is Cosette Pharmaceuticals’ 1st transaction in Australia.

M&A Deal Summary
Date 2025-02-20
Target Mayne Pharma
Sector Life Science
Buyer(s) Cosette Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 430M USD
Advisor(s) Jefferies (Financial)
Gilbert + Tobin
Arnold & Porter (Legal)

Target

Mayne Pharma

Salisbury South, Australia
Mayne Pharma is a specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally, either directly or through distribution partners and also provides contract development and manufacturing services. Mayne Pharma is based in Salisbury South, Australia.

Search 208,601 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Cosette Pharmaceuticals

Bridgewater, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Cosette Pharmaceuticals is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette Pharmaceuticals is based in Bridgewater, New Jersey.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Australia M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-20 Vyleesi

United States

Vyleesi is a treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Buy $171M
Mergr

Solution for

Product

Company

Legal